logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial

Laureillard D, Marcy O, Madec Y, Chea S, Chan S,  et al.
2013-10-23 • AIDS
2013-10-23 • AIDS
To analyze cases of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in the CAMbodian Early versus Late Introduction of Antiretrovirals (CAMELIA)...
Journal Article
|
Research

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C,  et al.
2011-10-20 • New England Journal of Medicine
2011-10-20 • New England Journal of Medicine
Tuberculosis remains an important cause of death among patients infected with the human immunodeficiency virus (HIV). Robust data are lacking with regard to the timing for the initiation...
Journal Article
|
Research

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C,  et al.
2014-08-01 • Clinical Infectious Diseases
2014-08-01 • Clinical Infectious Diseases
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency vir...
Journal Article
|
Research

Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment

Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N,  et al.
2008-09-11 • Antiviral therapy
2008-09-11 • Antiviral therapy
BACKGROUND
The long-term maintenance of antiretroviral therapy (ART) remains an important issue, especially in limited-resource settings where additional barriers exist. A cross-sect...
Journal Article
|
Research

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

Borand L, Madec Y, Laureillard D, Chou M, Marcy O,  et al.
2014-03-07 • PLOS One
2014-03-07 • PLOS One
OBJECTIVE
To assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.
Journal Article
|
Research

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia

Madec Y, Laureillard D, Pinoges LLP, Fernandez MAL, Prak N,  et al.
2007-01-30 • AIDS
2007-01-30 • AIDS
BACKGROUND: HAART efficacy was evaluated in a real-life setting in Phnom Penh (Médecins Sans Frontières programme) among severely immuno-compromised patients. METHODS: Factors associated...
Journal Article
|
Research

Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia

Ferradini LLF, Laureillard D, Prak N, Ngeth C, Fernandez MAL,  et al.
2007-11-12 • AIDS
2007-11-12 • AIDS
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunologica...